Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,220.00
Bid: 1,208.00
Ask: 1,218.00
Change: 20.00 (1.67%)
Spread: 10.00 (0.828%)
Open: 1,200.00
High: 1,226.00
Low: 1,194.00
Prev. Close: 1,200.00
AVON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Post Close Half Year Trading Update

6 Apr 2022 07:00

RNS Number : 3970H
Avon Protection PLC
06 April 2022
 

6 April 2022

Avon Protection plc

Post Close Half Year Trading Update

 

Avon Protection plc ("Avon Protection" or "the Group") today provides the following trading update for the six months ended 31 March 2022 ("HY22" or the "Period"). Unless otherwise stated, figures and commentary exclude the armor business.

 

Trading update

 

Trading in the first half reflects a continuation of some of the challenges seen in FY21, but with performance accelerating through the second quarter. Order intake was, as expected, lower than the comparable period last year reflecting a very strong first half in 2021, but, following the events in Ukraine, enquiries remain robust giving us confidence in order intake for the second half and beyond. Revenue for the Period was in line with expectations and ahead overall by c. 4%, with organic year-on-year performance broadly flat.

 

Profitability has however been impacted, in broadly even proportions, by a weaker than expected sales mix in the first half and additional manufacturing costs, notably in the helmets business, due to supply chain and process inefficiencies. As a result, the adjusted EBITDA margin for the period is expected to be approximately 10%.

 

Operationally, we have made good progress on the implementation of the $15m overhead cost saving programme announced in December 2021 (of which approximately half relates to overheads in the armor business and the remainder relates to the rest of the Group), including the closure of one of our U.S. offices and a change in management structure which streamlines the organisation into one focussed business.

 

Strategically, we are pleased with our continued progress, which includes the award of the U.S. DLA contract for the second-generation Advanced Combat Helmet in February and delivery of the next-generation Integrated Head Protection System for first article test scheduled for Q3. This momentum further reinforces our position as a leading provider of head protection to the U.S. military and provides a strong platform for future growth.

 

Outlook

 

The recent events in Ukraine have highlighted the criticality of our products and capabilities, and we have seen a notable increase in customer enquiry activity.

 

We have a number of active discussions ongoing with customers regarding potential incremental orders across both respiratory and helmet products. While these discussions remain ongoing and the quantum and timing of resultant orders are still to be determined, the impact of this growth in demand is most likely to be seen in FY23 and beyond, and as such the Board continues to have a range of expected full year revenue outcomes for FY22 consistent with market expectations.

 

Profitability in H2 is expected to improve versus H1 but will not offset the weakness experienced in the Period. Full year underlying earnings will therefore be lower than previously expected.

 

The second half margin will benefit from the adverse mix impact substantially unwinding along with the operational gearing effect of higher revenues and the initial contribution from the cost saving initiatives. The manufacturing inefficiencies described above are expected to improve as higher volumes are achieved. As a result, the Board expects EBITDA margins to recover progressively through the second half of the financial year and beyond, with the extent of this improvement in part dependent on the quantum and timing of incremental orders. Looking forward into FY23, the Group's profitability will benefit from the improved FY22 exit run-rate and the full year effect of the cost savings.

 

Armor business

 

In the period, as expected, armor revenues were in the low single digit $m pending final sign-off of first article testing of the DLA ESAPI body armor product. Combined with overheads, this business therefore operated at an EBITDA loss in the first half. We have continued with our steps for an orderly exit of this business once existing contracts are satisfied.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

"At Avon Protection, our purpose is to protect people and save lives. As a global leader in military-grade respiratory and head protection, we are seeing an increased demand for our products for both the short and longer term. We are working proactively with our key customers to confirm their requirements and maximise our available capacity in the short term. Longer term, this will create further opportunities and will likely result in mid-term capacity expansion to meet expected demand."

 

 

Notice of Results

The Group will release its results for the half year ended 31 March 2022 on 24 May 2022.

 

For further enquiries, please contact:

 

Avon Protection plc

Paul McDonald, Chief Executive Officer

01225 896 848

Rich Cashin, Chief Financial Officer

Rachel Stevens, Director of Investor Relations

MHP Communications

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection designs and produces life critical personal protection solutions for the world's militaries and first responders. With a portfolio that includes Chemical, Biological, Radiological, Nuclear ("CBRN"), respiratory and head protection products, Avon Protection's mission is to relentlessly advance the future of protection enhancing the performance, efficiency and capability of their customers whilst providing ever increasing levels of protection.

Avon Protection operates from six locations employing approximately 1,000 people and is listed on the London Stock Exchange (LSE: AVON).

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFSISLIEIIF
Date   Source Headline
3rd May 20248:34 amRNSHolding(s) in Company
18th Apr 20241:00 pmRNSHolding(s) in Company
8th Apr 202411:00 amRNSDirectors'/PDMR Shareholdings
5th Apr 20247:00 amRNSHolding(s) in Company
25th Mar 20244:30 pmRNSDirector/PDMR Shareholding
14th Mar 20249:17 amRNSAppointment of Non-Executive Director
6th Mar 20244:17 pmRNSDirectors'/PDMR Shareholdings
20th Feb 20245:00 pmRNSFinal Dividend Currency Exchange Rate
13th Feb 20247:00 amRNSHolding(s) in Company
8th Feb 20247:00 amRNSCapital Markets Event
6th Feb 202410:00 amRNSDirectors'/PDMR Shareholdings
5th Feb 20247:00 amRNSNext Generation IHPS Delivery Order
30th Jan 20241:00 pmRNSDirector/PDMR Shareholding
26th Jan 20242:00 pmRNSResult of AGM
26th Jan 20247:00 amRNSAGM Trading Update
25th Jan 20243:00 pmRNSPDMR Shareholdings
24th Jan 20247:00 amRNSU.S. Defense Logistics Agency helmet order
15th Jan 20247:00 amRNSGerman Navy underwater rebreather contract
11th Jan 20244:00 pmRNSDirectors'/PDMR Shareholdings
4th Jan 20247:00 amRNSNotice of Capital Markets Event
21st Dec 20233:00 pmRNSHolding(s) in Company
14th Dec 202310:00 amRNSPDMRs’ Interest in Shares
12th Dec 20233:00 pmRNSNotice of Annual Report, Accounts and 2024 AGM
7th Dec 20239:28 amRNSDirector/PDMR Shareholding
27th Nov 20239:00 amRNSHolding(s) in Company
23rd Nov 20236:00 pmRNSDirector/PDMR Shareholding
23rd Nov 202312:00 pmRNSDirector/PDMR Shareholding
23rd Nov 202312:00 pmRNSDirector/PDMR Shareholding
21st Nov 20232:00 pmRNSDirector/PDMR Shareholding
21st Nov 20237:00 amRNSPreliminary Results
7th Nov 20234:00 pmRNSDirector/PDMR Shareholding
20th Oct 20233:00 pmRNSNotification of PDMR Dealing
20th Oct 20231:00 pmRNSDirector/PDMR Shareholding
18th Oct 20236:00 pmRNSDirector/PDMR Shareholding
17th Oct 20233:00 pmRNSDirector/PDMR Shareholding
17th Oct 20233:00 pmRNSDirector/PDMR Shareholding
13th Oct 20237:00 amRNSTrading Update & Restatement of FY22 Results
6th Oct 20231:00 pmRNSDirectors'/PDMR Shareholdings
21st Aug 20233:00 pmRNSInterim Dividend Currency Exchange Rate
8th Aug 20231:00 pmRNSDirector/PDMR Shareholding
25th Jul 20232:00 pmRNSHolding(s) in Company
19th Jul 20234:00 pmRNSHolding(s) in Company
14th Jul 202312:00 pmRNSDirector/PDMR Shareholding
10th Jul 202312:00 pmRNSDirector/PDMR Shareholding
10th Jul 20238:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSU.S. Army Next-Generation Ballistic Helmet Order
27th Jun 20235:00 pmRNSHolding(s) in Company
20th Jun 20235:01 pmRNSHolding(s) in Company
7th Jun 20232:00 pmRNSHolding(s) in Company
6th Jun 20232:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.